GLP-1 drugs for children: what the FDA actually approved

What did @drjonesdc actually say?

The creator, who identifies as a chiropractor, shared a personal story about being nearly 300 pounds and pre-diabetic as a child. He speculated that GLP-1 medications could have "changed everything" for him. His core message: GLP-1 drugs are "a great idea" for obese children, but parents must frame them as "a tool and not a long-term solution." That framing matters, because it shifts a lot of clinical weight onto a parent-child conversation.

He stops short of saying anything reckless about dosing or specific drugs. His tone is personal and experiential, not prescriptive. He's drawing on lived experience with childhood obesity, which gives the video emotional resonance even when the clinical picture is more complicated than he lets on.

Does the science back this up?

Partially, yes. The FDA approved semaglutide (Wegovy) for adolescents aged 12 and older in December 2022, specifically for chronic weight management. That approval was based on the STEP TEENS trial (Weghuber et al., 2022, New England Journal of Medicine), which showed a 16.1% reduction in BMI in adolescents over 68 weeks versus 0.6% in the placebo group. That's a real, meaningful signal.

But the creator mentions an 11-year-old in the caption, and that's where the science gets thinner. Semaglutide is not FDA-approved for children under 12. Liraglutide (Saxenda) is approved down to age 12 for obesity. Tirzepatide has no pediatric approval at all. Using any of these drugs in a child younger than 12 would be off-label, which doesn't automatically make it wrong, but it demands a much more rigorous clinical conversation than a TikTok video can provide.

Long-term safety data for GLP-1 use in adolescents is still accumulating. We don't have decade-long outcome data for this population. That's not a reason to avoid treatment in severe cases, but it's a reason for caution that the video glosses over.

What did they get wrong (or right)?

The creator gets the mindset framing largely right. Research on adolescent obesity treatment consistently shows that behavioral readiness matters. His point that he "didn't want to believe" he had an issue until he decided to change at 16 maps onto what the literature calls autonomous motivation, a well-documented predictor of treatment success (Ryan and Deci, 2000, American Psychologist). Telling parents to communicate openly with their kids before starting GLP-1 therapy is genuinely good advice.

What he gets wrong, or at least oversimplifies, is the risk side of the equation. He calls GLP-1 use in obese children "a great idea" without acknowledging the gaps in pediatric long-term safety data, the absence of FDA approval for children under 12, or the very real concern about adolescents developing disordered relationships with medication-assisted weight loss before they've completed puberty. These aren't fringe concerns. Pediatric endocrinologists raise them routinely.

He also positions himself as someone who "helped thousands lose weight," and his credentials are listed as DC, meaning Doctor of Chiropractic. Chiropractors are not licensed to prescribe medications in any U.S. state. That credential gap isn't fatal to his personal story, but it matters when he's commenting on pharmaceutical therapy for children.

What should you actually know?

GLP-1 medications for adolescents with severe obesity are a legitimate, evidence-backed treatment option when managed by a qualified clinician. The STEP TEENS data is real and meaningful. But "a great idea" is doing a lot of work in a space that requires individualized medical assessment.

Any parent considering GLP-1 therapy for a child should be talking to a board-certified pediatric endocrinologist or a physician with specific training in adolescent weight management, not making decisions based on a TikTok from a chiropractor, however well-intentioned. The medication does not work in isolation. The STEP TEENS trial included lifestyle intervention alongside semaglutide, and the behavioral component is not optional.

The caption's framing of "11 year old on Ozempic" is also worth flagging. Ozempic is FDA-approved for type 2 diabetes in adults. It is not approved for pediatric weight management. Wegovy, a higher-dose semaglutide formulation, is approved for adolescents 12 and older. The distinction is regulatory and clinical, not just semantic.

• GLP-1 drugs for adolescents under 12 are off-label use and require documented clinical justification.
• No GLP-1 medication cures obesity. Weight often returns when the medication is stopped.
• Behavioral and nutritional support alongside medication is not optional. It's part of the evidence base.